Diagnosis and management of specific breast abnormalities
Agency for Healthcare Research and Quality

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Over 170,000 women are diagnosed with breast cancer yearly in the United States, incurring enormous individual and societal costs. The objective of this systematic review is to assess the quantity and quality of published evidence regarding specific current issues of diagnosis and management of women with breast disease.

Authors' conclusions
The best available evidence suggests that breast symptoms are evaluated initially by clinical breast exam and imaging study, with supplemental studies when the diagnosis is unclear. There is no evidence to support modifying the work-up of breast symptoms or mammographic abnormalities based on risk factors other than age. Strong evidence supports the necessity of performing excisional biopsy following stereotactic core needle biopsy (SCBX) diagnosis of atypical ductal hyperplasias (ADHs), as excisional biopsy often leads to a change in diagnosis. Preliminary evidence strongly suggests that Tamoxifen therapy markedly decreases the incidence of cancer following a diagnosis of lobular carcinoma in situ (LCIS) or atypical hyperplasia (AH), but it is associated with increased risk of endometrial cancer, thromboembolic disease, and other complications. While studies to date strongly suggest that sentinel node biopsy is successful in most breast cancer patients, long-term cancer outcomes and survival data are required before sentinel node biopsy could be considered the standard of care.

Project page URL
http://www.ahrq.gov/clinic/epcsums/abnorsum.htm

Indexing Status
Subject indexing assigned by CRD

MeSH
Breast Diseases /diagnosis; Breast Neoplasms

Language Published
English

Country of organisation
United States

Address for correspondence
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639; Email: martin.erlichman@ahrq.hhs.gov

AccessionNumber
32002000327